3SBio Inc.
1530
Peringkat dalam Saham
#3731
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Harga Saham
$1.77
Kapitalisasi Pasar
$4.43B
Perubahan (1 hari)
-2.80%
Perubahan (1 tahun)
-50.09%
Negara
CN
Perdagangan 3SBio Inc. (1530)
Kategori
Healthcare
Pendapatan untuk 3SBio Inc. (1530)
Pendapatan pada Jun 2026 TTM: $2.58B
Menurut laporan keuangan terbaru dari 3SBio Inc., pendapatan saat ini (TTM) adalah $2.58B. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $1.10B peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $994.42M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan 3SBio Inc. dari 2012 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $2.58B | 106.76% |
| 2024 | $1.25B | 13.01% |
| 2023 | $1.10B | 11.04% |
| 2022 | $994.42M | -0.96% |
| 2021 | $1.00B | 17.39% |
| 2020 | $855.33M | 11.99% |
| 2019 | $763.73M | 14.61% |
| 2018 | $666.40M | 16.10% |
| 2017 | $573.97M | 42.46% |
| 2016 | $402.90M | 56.37% |
| 2015 | $257.65M | 41.12% |
| 2014 | $182.57M | 26.51% |
| 2013 | $144.32M | 37.16% |
| 2012 | $105.22M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | 389.31% |
US
|
|
| $2.23B | -13.64% |
US
|
|
| $15.74B | 510.24% |
AU
|
|
| $6.02B | 133.38% |
NL
|
|
| - | - |
CH
|
